Home / Deep Research / Small Cell Lung Cancer

Small Cell Lung Cancer

1. Disease Information

2026-07-05
Falcon MONDO:0008433 Model: Edison Scientific Literature 48 citations

1. Disease Information

Overview

Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy accounting for approximately 10–15% of all lung cancers (zugazagoitia2024factsandhopes pages 1-1, redin2024smallcelllung pages 1-3). It is characterized by rapid growth, high metastatic capacity, early dissemination, and a strong epidemiologic and biologic association with tobacco carcinogens (megyesfalvi2023clinicalinsightsinto pages 1-2). Although SCLC is initially highly responsive to platinum-based chemotherapy, these responses are transient, and approximately 90% of patients experience rapid disease recurrence (redin2024smallcelllung pages 1-3). The 5-year survival rate remains dismally low at approximately 5–7% (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3).

Key Identifiers

  • MONDO ID: MONDO:0008433 (small cell lung carcinoma) (OpenTargets Search: small cell lung cancer)
  • ICD-10: C34 (malignant neoplasm of bronchus and lung; SCLC specified as small cell carcinoma)
  • ICD-O-3 Morphology: 8041/3 (small cell carcinoma, NOS)
  • MeSH: D055752 (Small Cell Lung Carcinoma)
  • Orphanet: ORPHA:70573

Synonyms and Alternative Names

Common synonyms include: small cell carcinoma of the lung, oat cell carcinoma, small cell undifferentiated carcinoma, and neuroendocrine carcinoma of the lung (small cell type). SCLC is classified among high-grade pulmonary neuroendocrine neoplasms.

Data Sources

Information in this report is derived from aggregated disease-level resources including comprehensive peer-reviewed reviews, SEER database analyses, clinical trial registries, and the OpenTargets Platform.

2. Etiology

Disease Causal Factors

The dominant causal factor in SCLC is tobacco smoke exposure. SCLC has the strongest epidemiologic link to tobacco carcinogens among all lung cancer subtypes, with the vast majority of patients being current or former heavy smokers (megyesfalvi2023clinicalinsightsinto pages 1-2). Genomically, SCLC is characterized by near-universal inactivation of the tumor suppressor genes TP53 (~92% of cases) and RB1 (~74%), which represent the initial steps in malignant transformation (redin2024smallcelllung pages 1-3). Additional recurrent genetic alterations include inactivating mutations in PTEN, CREBBP, EP300, KMT2D, NOTCH family genes, and activating mutations in PIK3CA (megyesfalvi2023clinicalinsightsinto pages 5-5, OpenTargets Search: small cell lung cancer). MYC family amplification (MYC, MYCL, MYCN) is also frequent (megyesfalvi2023clinicalinsightsinto pages 5-5).

Risk Factors

Genetic risk factors: TP53 and RB1 co-alteration is the defining molecular event essential for SCLC pathogenesis (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3). An integrative analysis of 3,600 real-world SCLC cases identified new genetic subtypes including STK11-mutant tumors (1.7%) and TP53/RB1 wild-type tumors (5.5%), of which 12.7% were HPV-positive. CCNE1 amplification was associated with decreased overall survival, while 4q12 gene amplifications were associated with increased survival (OpenTargets Search: small cell lung cancer).

Environmental risk factors: Tobacco smoking is the predominant environmental risk factor. Additional environmental exposures including radon gas and air pollution contribute to lung cancer risk (huang2025molecularsubtypesand pages 1-2). The disease predominantly affects elderly male heavy smokers (huang2023incidencesurvivalcomparison pages 1-2).

Protective Factors

Smoking cessation is the primary protective factor. The declining incidence of SCLC in the United States over the past two decades (48.6% decrease from 2000 to 2020) is attributed to reduced smoking rates (uprety2025trendsinthe pages 1-2, uprety2025trendsinthe pages 2-4).

3. Phenotypes

Symptoms and Clinical Signs

SCLC commonly presents with centrally located hilar or mediastinal masses, cough, dyspnea, chest pain, hemoptysis, and weight loss. Due to its rapid doubling time and early metastatic spread, approximately 70–80% of patients present with extensive-stage (metastatic) disease at diagnosis (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3).

Paraneoplastic Syndromes

SCLC is notably associated with paraneoplastic syndromes due to its neuroendocrine differentiation. These include: - SIADH (Syndrome of Inappropriate Antidiuretic Hormone secretion) — the most common paraneoplastic syndrome in SCLC - Lambert-Eaton Myasthenic Syndrome (LEMS) — characterized by calcium-channel antibodies (megyesfalvi2023clinicalinsightsinto pages 27-27) - Cushing syndrome — ectopic ACTH production - Anti-Hu antibody-related paraneoplastic syndromes — presenting with progressive dysautonomia and neuropathy (megyesfalvi2023clinicalinsightsinto pages 27-27)

Patients with neurologic paraneoplastic syndromes have been associated with improved prognosis and increased tumor-infiltrating lymphocytes (megyesfalvi2023clinicalinsightsinto pages 27-27).

Quality of Life Impact

SCLC profoundly impacts quality of life through rapid symptom progression, metastatic disease burden (particularly brain metastases), and treatment-related toxicity. The aggressive disease course and short survival significantly affect functional status and psychosocial well-being.

4. Genetic/Molecular Information

Causal Genes and Pathogenic Variants

The genes coding for the tumor suppressors p53 (TP53) and retinoblastoma (RB1) are inactivated in the vast majority of SCLC tumors. These two deleterious genetic events represent the initial steps in SCLC development, making them essential for a lung epithelial cell to progress toward malignancy (huang2025molecularsubtypesand pages 1-2, megyesfalvi2023clinicalinsightsinto pages 1-2). TP53 is mutated in approximately 92% of cases and RB1 in approximately 74% (redin2024smallcelllung pages 1-3).

Additional recurrently altered genes include: - PTEN (pathway: PI3K-AKT-mTOR) — more frequent alterations in brain metastases (OpenTargets Search: small cell lung cancer) - CREBBP and EP300 — chromatin remodeling/histone acetyltransferase genes (OpenTargets Search: small cell lung cancer) - KMT2D — lysine methyltransferase involved in epigenetic regulation (OpenTargets Search: small cell lung cancer) - NOTCH family genes — tumor suppressive role in NE lineage (megyesfalvi2023clinicalinsightsinto pages 5-5) - PIK3CA — activating mutations (megyesfalvi2023clinicalinsightsinto pages 5-5) - MYC/MYCL/MYCN — amplifications driving aggressive phenotype (megyesfalvi2023clinicalinsightsinto pages 5-5) - SMARCA4 — catalytic subunit of SWI/SNF complex, mutations in 1.5–4% of cases (redin2024smarca4controlsstate pages 1-2) - KEAP1 — may contribute to SCLC pathogenesis (OpenTargets Search: small cell lung cancer)

Molecular Subtypes

Recent multi-omic studies have revealed distinct molecular subtypes driven by lineage-defining transcription factors (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3):

Table (click to expand)
Subtype Transcription factor / defining program Approx. frequency Neuroendocrine status Key molecular features / pathway enrichment Suggested targeted therapies / vulnerabilities
SCLC-A ASCL1 ~70% NE-high Canonical neuroendocrine subtype; enriched for BCL2, DLL3, SOX2, RET, MYCL1 and ASCL1-driven lineage programs (redin2024smallcelllung pages 1-3, huang2025molecularsubtypesand pages 7-9, huang2025molecularsubtypesand pages 2-4) DLL3-targeting agents (e.g., tarlatamab), BCL2 inhibitors (venetoclax), LSD1 inhibitors, HDAC inhibitors; RET/BCL2-directed strategies under study (huang2025molecularsubtypesand pages 7-9, patel2023smallcelllung pages 1-2)
SCLC-N NEUROD1 ~15% NE-high More aggressive/proliferative state; associated with MYC co-expression/amplification, neuronal signaling, chemoresistance, and elevated AURKA/AURKB dependence (redin2024smallcelllung pages 1-3, huang2025molecularsubtypesand pages 7-9, huang2025molecularsubtypesand pages 2-4) Aurora kinase inhibitors (e.g., alisertib), MYC-directed approaches, cell-cycle pathway targeting; IMPDH inhibitors proposed in review literature (huang2025molecularsubtypesand pages 7-9, huang2025molecularsubtypesand pages 2-4)
SCLC-P POU2F3 7–15% NE-low / non-NE Tuft-cell-like subtype; depends on IGF1R signaling and shows relative DNA repair deficiencies; transcriptomically distinct from classic NE SCLC (redin2024smallcelllung pages 1-3, huang2025molecularsubtypesand pages 2-4, redin2024smallcelllung pages 4-6) IGF1R inhibitors, PARP inhibitors, DNA-damaging agents, SWI/SNF ATPase-directed approaches proposed for selected tumors (huang2025molecularsubtypesand pages 7-9, huang2025molecularsubtypesand pages 2-4)
SCLC-Y YAP1 (debated as stable subtype in some studies) 3–10% NE-low / non-NE Linked to low-NE state, lineage plasticity, EMT/non-NE features, and therapy resistance; YAP/Notch/REST programs implicated. Some reviews note this category is biologically less stable or inconsistently reproduced across datasets (redin2024smallcelllung pages 1-3, huang2025molecularsubtypesand pages 2-4, redin2024smallcelllung pages 11-13, redin2024smallcelllung pages 13-14) No single standard targeted therapy; candidate approaches include ERBB pathway targeting in specific low-NE/YAP-associated transitions and broader plasticity-directed/epigenetic strategies (huang2025molecularsubtypesand pages 13-15, redin2024smarca4controlsstate pages 1-2, redin2024smallcelllung pages 13-14)
SCLC-I Inflamed / immune program rather than dominant ASCL1/NEUROD1/POU2F3 Not firmly fixed; distinct subset Often NE-low / inflamed Characterized by inflamed gene signatures, higher HLA/antigen-presentation, immune checkpoint expression, mesenchymal features, and greater immune-cell infiltration versus NE-high “immune desert” tumors (zugazagoitia2024factsandhopes pages 1-1, megyesfalvi2023clinicalinsightsinto pages 6-7) Greatest rationale for immune checkpoint blockade; biomarker-enriched immunotherapy strategies and combination immunotherapy approaches are emphasized (zugazagoitia2024factsandhopes pages 1-1, chen2024advancesinpredictive pages 2-4, megyesfalvi2023clinicalinsightsinto pages 6-7)

Table: This table summarizes the main molecular subtypes of small cell lung cancer, their defining transcriptional programs, approximate frequencies, biologic features, and leading therapeutic hypotheses. It is useful for mapping subtype biology to emerging precision-treatment strategies.

Epigenetic Information

Epigenetic regulation plays a critical role in SCLC biology. SMARCA4, the catalytic subunit of the SWI/SNF chromatin remodeling complex, controls neuroendocrine state plasticity by binding to ASCL1 and NEUROD1 gene loci and enhancing chromatin accessibility (redin2024smarca4controlsstate pages 1-2). State transitions in SCLC appear to be epigenetically rather than mutationally determined, with SMARCA4 inhibition inducing loss of NE features and activation of non-NE signaling pathways (redin2024smarca4controlsstate pages 1-2). DNA methylation patterns correlate with EZH2 expression and define clinically relevant subtypes (redin2024smallcelllung pages 11-13). CREBBP loss sensitizes tumors to HDAC inhibition (redin2024smallcelllung pages 13-14).

5. Environmental Information

Environmental and Lifestyle Factors

Tobacco smoking is the dominant environmental risk factor, with SCLC having the strongest association with tobacco carcinogens among lung cancer subtypes (megyesfalvi2023clinicalinsightsinto pages 1-2). The declining incidence of SCLC directly parallels declining smoking rates in the United States, with the age-adjusted incidence rate dropping from 9 per 100,000 in 2000 to 4.6 per 100,000 in 2020 (uprety2025trendsinthe pages 1-2). Additional environmental exposures including radon gas and air pollution contribute to lung carcinogenesis risk (huang2025molecularsubtypesand pages 1-2).

Infectious Agents

While not a primary etiologic factor, HPV-positive SCLC has been identified in a subset of TP53/RB1 wild-type tumors, with 12.7% of this uncommon genotype testing HPV-positive (OpenTargets Search: small cell lung cancer).

6. Mechanism / Pathophysiology

Molecular Pathways

SCLC pathogenesis involves multiple interconnected signaling cascades: - TP53/RB1 inactivation pathway: Near-universal loss of both tumor suppressors eliminates cell cycle control and senescence barriers, enabling indefinite proliferation (papavassiliou2024p53andrb pages 4-5) - MYC signaling: MYC amplification drives NE-low phenotype with high NEUROD1 expression and promotes subtype transition from SCLC-A to SCLC-N (megyesfalvi2023clinicalinsightsinto pages 5-5) - Notch signaling: Activated by MYC, mediates NE plasticity and lineage switching (megyesfalvi2023clinicalinsightsinto pages 5-5) - BCL2 anti-apoptotic pathway: Elevated BCL2 expression is a transcriptional target of ASCL1, suppressing apoptosis (megyesfalvi2023clinicalinsightsinto pages 5-5) - PI3K-AKT-mTOR pathway: PTEN deletions and PIK3CA mutations activate this pro-survival cascade (megyesfalvi2023clinicalinsightsinto pages 5-5) - YAP/Notch/REST network: Controls neuroendocrine cell fate determination (redin2024smallcelllung pages 11-13)

GO Terms: GO:0008283 (cell population proliferation), GO:0006915 (apoptotic process), GO:0007219 (Notch signaling pathway)

Cellular Processes and Cell Types

SCLC can arise from multiple pulmonary cell types including basal cells, neuroendocrine cells, club cells, and alveolar type 2 (AT2) cells (redin2024smallcelllung pages 4-6). The SCLC-P subtype shows transcriptomic similarity to tuft cells, suggesting tuft cell precursors as a possible origin (redin2024smallcelllung pages 4-6). Neuroendocrine cells of the lung are characterized by dense-core granules and NE marker expression (megyesfalvi2023clinicalinsightsinto pages 5-5).

CL terms: CL:1000223 (lung neuroendocrine cell), CL:0000083 (epithelial cell of lung), CL:0002063 (type II pneumocyte)

Immune Evasion Mechanisms

SCLC employs multiple immune evasion strategies: - T cell exclusion: NE-high SCLCs are characterized as "immune desert" tumors with minimal infiltrating immune cells (megyesfalvi2023clinicalinsightsinto pages 6-7) - MHC-class I downregulation: Reduced antigen processing and presentation machinery (zugazagoitia2024factsandhopes pages 1-1) - Surface glycolipid/glycoprotein overexpression: GD2 ganglioside engages siglec7 on macrophages and NK cells to suppress immunity (zugazagoitia2024factsandhopes pages 2-3) - CD47 overexpression: Inhibits macrophage-mediated phagocytosis through SIRPα binding (zugazagoitia2024factsandhopes pages 2-3) - PD-L1 upregulation: T-cell checkpoint immune inhibitory signaling (zugazagoitia2024factsandhopes pages 2-3)

Tumor Microenvironment

The SCLC tumor microenvironment is characterized by abundant, aggressively growing cancer cells that vastly outnumber immune cells, with minimal interdigitated tumor-associated immune stroma (zugazagoitia2024factsandhopes pages 2-3). However, the SCLC-I (inflamed) subtype demonstrates higher immune-cell infiltration, elevated checkpoint and HLA expression, and greater potential benefit from immunotherapy (megyesfalvi2023clinicalinsightsinto pages 6-7).

7. Anatomical Structures Affected

Primary Organs

  • Lung (UBERON:0002048) — primary site; tumors typically arise centrally in hilar/mediastinal regions
  • Brain — frequent metastatic site; contrast-enhanced MRI is standard for evaluation (megyesfalvi2023clinicalinsightsinto pages 10-11)
  • Liver — common metastatic site; liver metastasis is most common distant site in SCLC (OpenTargets Search: small cell lung cancer)
  • Bone — frequent metastatic site
  • Adrenal glands — common metastatic site

Tissue and Cell Level

8. Temporal Development

Onset

SCLC predominantly affects adults aged 60–80 years, with the disease being rare in patients under 40. The peak incidence is in the seventh decade of life (huang2023incidencesurvivalcomparison pages 1-2). Onset is typically subacute to acute, with rapid symptom progression over weeks to months.

Progression and Staging

SCLC is staged using two systems: 1. Veterans Affairs Lung Study Group (VALSG): Limited-stage (LS-SCLC, ~30% of patients) vs. Extensive-stage (ES-SCLC, ~70% of patients) (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3) 2. AJCC TNM staging system: Increasingly used for prognostic refinement

Disease progression is extremely rapid, with a median doubling time of approximately 30 days. Despite high initial chemosensitivity, drug resistance develops rapidly, and recurrence occurs in the majority of patients (megyesfalvi2023clinicalinsightsinto pages 1-2).

Disease Course

9. Inheritance and Population

Epidemiology

SCLC is not a heritable Mendelian disorder but rather a sporadic malignancy driven by somatic mutations accumulated through carcinogenic exposure.

Incidence: A comprehensive SEER database analysis of 188,426 SCLC patients (2000–2020) demonstrated that the age-adjusted incidence rate declined by an average of 3% annually, from 9 per 100,000 in 2000 to 4.6 per 100,000 in 2020 — a 48.6% overall decrease (uprety2025trendsinthe pages 1-2, uprety2025trendsinthe pages 2-4). In 2023, there were approximately 238,340 new lung cancer cases in the United States, with SCLC comprising approximately 13% (chen2024aretrospectivestudy pages 1-2).

Population Demographics: - Incidence declines were observed across all age groups, sexes, and races, with younger groups (<50 years) showing sharper declines (APC -6.4%) compared to older populations (80+, APC -1.6%) (uprety2025trendsinthe pages 2-4) - Males experienced steeper incidence declines (-3.5% APC) than females (-2.5% APC) (uprety2025trendsinthe pages 2-4) - The disease predominantly affects elderly male heavy smokers (huang2023incidencesurvivalcomparison pages 1-2) - Five-year overall survival remains less than 10–15% across all stages (chen2024aretrospectivestudy pages 1-2, huang2023incidencesurvivalcomparison pages 1-2)

Survival trends: Despite declining incidence and incidence-based mortality (from 6.6 in 2005 to 3.5 in 2020), 1-year relative survival rates have not improved significantly over the two-decade period, indicating the need for more effective systemic therapies (uprety2025trendsinthe pages 1-2).

10. Diagnostics

Clinical Tests and Imaging

Tissue Diagnosis

Pathology

Characteristic cytologic findings include small blue cells approximately 1.5 times the size of lymphocytes with scant cytoplasm, hyperchromatic oval or elongated nuclei with well-developed nuclear molding, and a finely dispersed "salt and pepper" chromatin pattern (megyesfalvi2023clinicalinsightsinto pages 10-11).

Biomarkers

11. Outcome/Prognosis

Survival and Mortality

Prognostic Factors

Age, sex, disease stage (TNM), T stage, N stage, M stage, liver metastasis, brain metastasis, bone metastasis, and treatment modality are independent prognostic factors (huang2023incidencesurvivalcomparison pages 1-2). CCNE1 amplification is associated with decreased survival, while 4q12 amplifications are associated with improved survival (OpenTargets Search: small cell lung cancer). Patients with neurologic paraneoplastic syndromes show improved prognosis (megyesfalvi2023clinicalinsightsinto pages 27-27).

12. Treatment

Disease-Target Associations (OpenTargets)

The following table summarizes the key therapeutic targets identified from OpenTargets (MONDO:0008433) and the supporting literature:

Table (click to expand)
Target Gene Symbol Target Name Association Score Key Evidence (approved drugs, clinical stage, relevant PMIDs) Role in SCLC
RB1 RB transcriptional corepressor 1 0.73 OpenTargets lists 5 supporting evidence items for MONDO_0008433, including literature PMIDs 34430610, 35792876, 26168399, 22941188, 24071849; recurrently identified as a defining SCLC tumor suppressor alteration (OpenTargets Search: small cell lung cancer, megyesfalvi2023clinicalinsightsinto pages 1-2) Core tumor suppressor; near-universal functional loss helps drive cell-cycle deregulation and lineage transformation in SCLC (OpenTargets Search: small cell lung cancer, megyesfalvi2023clinicalinsightsinto pages 1-2)
TOP1 DNA topoisomerase I 0.65 OpenTargets includes approval-stage evidence and clinical report IDs linked to TOP1-directed therapy plus regulatory records; literature and clinical evidence support topoisomerase-targeting treatment relevance in SCLC (OpenTargets Search: small cell lung cancer, patel2023smallcelllung pages 1-2) Therapeutic target class rather than lineage driver; relevant because SCLC is highly chemotherapy-sensitive initially and topoisomerase-directed agents are part of the treatment landscape, including irinotecan-based regimens and lurbinectedin-era development context (OpenTargets Search: small cell lung cancer, patel2023smallcelllung pages 1-2)
TP53 Tumor protein p53 0.63 OpenTargets lists 5 evidence items including PMIDs 35340160, 37534137, 40113013, 30279957, 31737176; repeatedly described as nearly universal inactivation in SCLC (OpenTargets Search: small cell lung cancer, megyesfalvi2023clinicalinsightsinto pages 1-2) Foundational tumor suppressor loss; with RB1 inactivation it is a hallmark initiating event in most SCLC and underlies genomic instability, apoptosis evasion, and aggressive behavior (OpenTargets Search: small cell lung cancer, megyesfalvi2023clinicalinsightsinto pages 1-2)
CD274 (PD-L1) CD274 molecule 0.62 OpenTargets includes 5 literature-backed evidence items (PMIDs 32773010, 39810133, 38132164, 37040387, 31315783); clinical use supported by atezolizumab and durvalumab with platinum-etoposide in ES-SCLC (OpenTargets Search: small cell lung cancer, chen2024advancesinpredictive pages 2-4, bonanno2024realworldimpactof pages 1-2) Immune checkpoint target; PD-L1-axis blockade is part of current first-line standard therapy for extensive-stage SCLC, though benefits are modest and biomarker performance is imperfect (chen2024advancesinpredictive pages 2-4, bonanno2024realworldimpactof pages 1-2)
CDK6 Cyclin dependent kinase 6 0.62 OpenTargets lists literature PMIDs 39136283 and 35117162 plus approval/phase 4 evidence; CDK4/6 dependency is most relevant in RB1-retained subsets (OpenTargets Search: small cell lung cancer) Cell-cycle kinase target; may represent an actionable vulnerability in uncommon RB1-proficient SCLC tumors rather than classic RB1-null disease (OpenTargets Search: small cell lung cancer)
CDK4 Cyclin dependent kinase 4 0.59 OpenTargets lists literature PMIDs 39136283 and 31199581 plus approval/phase 4 evidence; CDK4/6 inhibitor sensitivity has been linked to RB1-expressing SCLC subsets (OpenTargets Search: small cell lung cancer) Similar to CDK6, supports a precision-medicine niche in RB1-intact SCLC, where CDK4/6 blockade may suppress tumor growth (OpenTargets Search: small cell lung cancer)
DLL3 Delta like canonical Notch ligand 3 0.59 OpenTargets includes literature PMIDs 38468968, 41331586, 31819500, 31452726 and approval-stage evidence; DLL3-targeted BiTE therapy tarlatamab is highlighted in recent SCLC therapeutic reviews and trials (OpenTargets Search: small cell lung cancer, megyesfalvi2023clinicalinsightsinto pages 19-20, zugazagoitia2024factsandhopes pages 7-8) Lineage-associated surface antigen enriched in neuroendocrine SCLC; major emerging therapeutic target for bispecific T-cell engagers, ADCs, and CAR-T approaches (megyesfalvi2023clinicalinsightsinto pages 19-20, zugazagoitia2024factsandhopes pages 7-8)
TOP2A DNA topoisomerase II alpha 0.58 OpenTargets includes literature PMIDs 38806610, 37407689, 39921782 plus approval-stage evidence; mechanistically relevant to etoposide-based therapy backbone in SCLC (OpenTargets Search: small cell lung cancer, patel2023smallcelllung pages 1-2) Cytotoxic therapy target linked to the etoposide backbone of standard treatment; reflects persistent dependence of SCLC management on DNA damage and topoisomerase-directed chemotherapy (OpenTargets Search: small cell lung cancer, patel2023smallcelllung pages 1-2)

Table: This table summarizes the leading OpenTargets disease-target associations for small cell lung cancer (MONDO_0008433) and links them to their clinical or biological roles in SCLC. It is useful for distinguishing foundational drivers such as TP53/RB1 from actionable therapeutic targets such as PD-L1, DLL3, CDK4/6, and topoisomerases.

Standard First-Line Therapy

Limited-Stage SCLC: - Concurrent thoracic radiotherapy with platinum-etoposide chemotherapy (cisplatin or carboplatin plus etoposide) (megyesfalvi2023clinicalinsightsinto pages 1-2) - Prophylactic cranial irradiation (PCI) for responders - MAXO: MAXO:0000058 (chemotherapy), MAXO:0000014 (radiation therapy)

Extensive-Stage SCLC: - Platinum-etoposide chemotherapy combined with anti-PD-L1 immunotherapy (atezolizumab or durvalumab) — current standard of care established by IMpower133 and CASPIAN trials (megyesfalvi2023clinicalinsightsinto pages 1-2, chen2024advancesinpredictive pages 2-4, bonanno2024realworldimpactof pages 1-2) - Atezolizumab + carboplatin/etoposide: median OS 12.3 vs. 10.3 months (chen2024advancesinpredictive pages 2-4) - Durvalumab + platinum/etoposide: median OS 12.9 vs. 10.5 months (chen2024advancesinpredictive pages 2-4) - MAXO: MAXO:0001480 (immune checkpoint inhibitor therapy)

Real-world impact: After introduction of chemo-immunotherapy (May 2020), 12-month OS rate increased from 15% to 28% (p=0.03), and 18-month OS rate from 2.1% to 12% (p=0.009), with reduced hospitalization duration (bonanno2024realworldimpactof pages 1-2, bonanno2024realworldimpactof pages 3-5).

Second-Line and Relapsed SCLC

Emerging Targeted Therapies

DLL3-Targeting Agents: - Tarlatamab (AMG 757): DLL3×CD3 bispecific T-cell engager; achieved 23.4% ORR with median duration of response of 12.3 months in heavily pretreated ES-SCLC (megyesfalvi2023clinicalinsightsinto pages 19-20, zugazagoitia2024factsandhopes pages 7-8). FDA approved for relapsed SCLC in 2024.

Antibody-Drug Conjugates (ADCs): - Ifinatamab deruxtecan (I-DXd): Anti-B7-H3 ADC; 53% response rate in SCLC patients (patel2023smallcelllung pages 6-8) - Sacituzumab govitecan: Anti-TROP2 ADC; 18% ORR, 7.1 month median OS (patel2023smallcelllung pages 6-8)

PARP Inhibitors: - Rucaparib + nivolumab: clinical benefit in 56% of patients, 7.4 months median PFS (megyesfalvi2023clinicalinsightsinto pages 19-20) - Talazoparib + atezolizumab maintenance: modest PFS improvement in SLFN11-positive tumors (zugazagoitia2024factsandhopes pages 5-6)

CDK4/6 Inhibitors: - RB1-proficient SCLC (~14% of cases) shows sensitivity to palbociclib and abemaciclib (OpenTargets Search: small cell lung cancer)

Anti-Angiogenic Combinations: - ETER701: Benmelstobart + anlotinib + etoposide/carboplatin achieved unprecedented median OS of 19.3 months in ES-SCLC (cheng2024benmelstobartanlotiniband pages 1-2, zugazagoitia2024factsandhopes pages 3-3)

Key Clinical Trials

Table (click to expand)
NCT Number Trial Name/Description Phase Status Enrollment Key Intervention
NCT04234607 ETER701: first-line extensive-stage SCLC trial of benmelstobart + anlotinib + etoposide/carboplatin versus comparator arms; reported median OS 19.3 vs 11.9 months for triplet vs chemotherapy alone (cheng2024benmelstobartanlotiniband pages 1-2, zugazagoitia2024factsandhopes pages 3-3) Phase 3 Completed/reported 738 Benmelstobart (PD-L1 inhibitor) + anlotinib + etoposide/carboplatin
NCT02763579 IMpower133: landmark first-line ES-SCLC trial establishing atezolizumab + carboplatin/etoposide as a standard option; median OS 12.3 vs 10.3 months versus placebo + chemotherapy (chen2024advancesinpredictive pages 2-4, bonanno2024realworldimpactof pages 1-2) Phase 3 Completed 403 Atezolizumab + carboplatin + etoposide
NCT03043872 CASPIAN: landmark first-line ES-SCLC trial establishing durvalumab + platinum/etoposide; median OS 12.9 vs 10.5 months versus chemotherapy alone (chen2024advancesinpredictive pages 2-4, bonanno2024realworldimpactof pages 1-2) Phase 3 Completed 805 Durvalumab + etoposide + platinum
NCT03319940 First-in-human tarlatamab (AMG 757) study in relapsed/advanced SCLC and other NECs; established clinical activity for DLL3-targeted BiTE therapy (zugazagoitia2024factsandhopes pages 7-8) Phase 1 Active, not recruiting 269 Tarlatamab monotherapy
NCT05361395 First-line tarlatamab combination trial in ES-SCLC (DeLLphi-305 concept): tarlatamab with carboplatin, etoposide, and PD-L1 inhibitor (sen2024emergingadvancesin pages 1-3) Phase 1 Active, not recruiting 184 Tarlatamab + carboplatin + etoposide + PD-L1 inhibitor
NCT05740566 Phase 3 tarlatamab trial in relapsed SCLC referenced through DLL3/CD3 evidence; major confirmatory randomized program for DLL3-targeted BiTE therapy (OpenTargets Search: small cell lung cancer) Phase 3 Ongoing NR Tarlatamab versus standard therapy
NCT06203210 Phase 3 trial of ifinatamab deruxtecan versus physician’s choice in relapsed SCLC (patel2023smallcelllung pages 6-8, OpenTargets Search: small cell lung cancer) Phase 3 Recruiting 540 Ifinatamab deruxtecan (B7-H3 ADC)
NCT07218146 DLLEVATE: Phase 3 trial of ZL-1310 versus investigator’s choice in relapsed SCLC (OpenTargets Search: small cell lung cancer) Phase 3 Recruiting 480 ZL-1310
NCT06498479 ARTEMIS-008: Phase 3 trial of HS-20093 compared with topotecan in relapsed SCLC (OpenTargets Search: small cell lung cancer) Phase 3 Recruiting 460 HS-20093 versus topotecan
NCT07015892 Dose-escalation radiotherapy in limited-stage SCLC randomized Phase 3 study (OpenTargets Search: small cell lung cancer) Phase 3 Recruiting 300 Dose-escalated thoracic radiotherapy
NCT04402788 RAPTOR: addition of radiation therapy to maintenance atezolizumab in extensive-stage SCLC after chemoimmunotherapy (OpenTargets Search: small cell lung cancer) Phase 2/3 Recruiting 138 Thoracic radiation + atezolizumab

Table: This table summarizes landmark and actively recruiting small cell lung cancer trials identified in the research, spanning chemoimmunotherapy, DLL3-targeted therapy, antibody-drug conjugates, and radiation strategies. It is useful for quickly comparing the current clinical development landscape and the studies that shaped present standards of care.

Telomere-Targeting Approaches

6-Thio-2'-deoxyguanosine (6TdG), currently in phase II clinical trials, is a nucleoside analog preferentially incorporated by telomerase into telomeres, leading to telomere dysfunction. In SCLC preclinical models, low intermittent doses inhibited tumor growth, reduced metastatic burden, depleted cancer-initiating cells, and activated innate and adaptive anti-tumor immune responses through STING signaling (eglenenpolat2024atelomeretargetingdrug pages 1-2).

13. Prevention

Primary Prevention

  • Smoking cessation and prevention remain the most important preventive strategies. The 48.6% decline in SCLC incidence from 2000–2020 directly correlates with reduced smoking rates (uprety2025trendsinthe pages 1-2, uprety2025trendsinthe pages 2-4)
  • Radon mitigation in homes and workplaces
  • Air pollution reduction policies

Secondary Prevention (Screening)

Low-dose CT (LDCT) lung cancer screening programs detect predominantly non-small cell lung cancers. SCLC is less commonly detected by screening due to its rapid growth kinetics and interval presentation. However, broader adoption of LDCT screening may increase early-stage SCLC detection.

Tertiary Prevention

  • Prophylactic cranial irradiation (PCI): Reduces brain metastasis incidence in responding LS-SCLC patients
  • Thoracic radiotherapy consolidation: Addition of TRT showed significant survival benefits in ES-SCLC patients receiving immunotherapy plus chemotherapy (median PFS 10.76 vs. 7.63 months; median OS 21.67 vs. 16.6 months) (OpenTargets Search: small cell lung cancer)

14. Other Species / Natural Disease

SCLC is primarily a human disease and does not commonly occur naturally in other species in an identical form. However, spontaneous neuroendocrine tumors have been reported in rodents and dogs. Comparative pathology studies utilize orthologous genes (murine Trp53 and Rb1) in genetically engineered models to recapitulate human disease features.

15. Model Organisms

Genetically Engineered Mouse Models (GEMMs)

The foundational SCLC GEMM was generated by Meuwissen et al. using lung-specific compound deletion of Trp53 and Rb1 genes, which led to SCLC tumor development resembling human disease. A key finding was the long tumor latent period of 9–12 months after genetic deletion, indicating that secondary oncogenic alterations are required for malignant transformation (papavassiliou2024p53andrb pages 4-5). Additional GEMMs incorporating further genetic aberrations (e.g., Rbl2/p130 deletion, Myc overexpression, Pten deletion) alongside Trp53/Rb1 loss showed shorter latency periods (papavassiliou2024p53andrb pages 4-5).

A GEMM with a mutant c-Myc allele demonstrated tumor progression and metastasis associated with subtype transition from SCLC-A to SCLC-N and low-NE YAP1+ SCLC, modeling the plasticity observed in human disease (redin2024smarca4controlsstate pages 1-2).

Cell Lines

Established SCLC cell lines include mouse-derived lines (984 from Rb/p53 KO mice; RPP from Rb/p130/p53 triple KO) and human lines (H1048, H69, H510, H841) (eglenenpolat2024atelomeretargetingdrug pages 1-2).

Patient-Derived Xenografts (PDXs)

PDX models maintain the molecular and biologic features of original patient tumors and are used for preclinical drug testing. They have been employed for ChIPseq characterization of epigenetic regulators like SMARCA4 and for testing novel therapeutic combinations (redin2024smarca4controlsstate pages 1-2, eglenenpolat2024atelomeretargetingdrug pages 1-2).

Syngeneic and Humanized Models

Syngeneic SCLC models are critical for studying immune responses in vivo and testing immunotherapeutic approaches, including 6TdG studies that demonstrated immune-dependent anti-tumor activity (eglenenpolat2024atelomeretargetingdrug pages 1-2).

Model Limitations

  • Long latency periods in GEMMs (9–12 months) limit throughput
  • In vitro TP53/RB1-null cells demonstrate indefinite proliferation but not spontaneous malignant transformation, representing a precancerous state rather than fully malignant SCLC (papavassiliou2024p53andrb pages 4-5)
  • PDX models lack an intact immune system (requiring humanized mouse approaches)
  • Cell line models may not capture the full intratumoral heterogeneity and plasticity of patient tumors
  • Single-biopsy molecular classification may miss intratumoral subtype mixing (redin2024smallcelllung pages 4-6)

Summary

Small cell lung cancer remains one of the most challenging malignancies in oncology, defined by its aggressive biology, near-universal TP53/RB1 inactivation, and rapid chemoresistance development. The molecular reclassification into transcription factor-defined subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-Y/I) has opened new avenues for precision medicine (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3). While chemo-immunotherapy has become the standard of care for ES-SCLC with modest survival improvements, emerging therapies including DLL3-targeting bispecific T-cell engagers (tarlatamab), antibody-drug conjugates, and anti-angiogenic combinations (ETER701) show promising activity (megyesfalvi2023clinicalinsightsinto pages 19-20, zugazagoitia2024factsandhopes pages 7-8, cheng2024benmelstobartanlotiniband pages 1-2). The integration of multi-omic data, dynamic liquid biopsy monitoring, and subtype-specific therapeutic strategies represents the future direction for improving outcomes in this devastating disease (huang2025molecularsubtypesand pages 13-15).

References

  1. (zugazagoitia2024factsandhopes pages 1-1): Jon Zugazagoitia, Handerson Osma, Javier Baena, Alvaro C. Ucero, and Luis Paz-Ares. Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2872-2883, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-1159, doi:10.1158/1078-0432.ccr-23-1159. This article has 29 citations.

  2. (redin2024smallcelllung pages 1-3): Esther Redin, Álvaro Quintanal-Villalonga, and Charles M. Rudin. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends in Cancer, 10:935-946, Oct 2024. URL: https://doi.org/10.1016/j.trecan.2024.07.008, doi:10.1016/j.trecan.2024.07.008. This article has 47 citations and is from a peer-reviewed journal.

  3. (megyesfalvi2023clinicalinsightsinto pages 1-2): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  4. (huang2025molecularsubtypesand pages 1-2): Daoyuan Huang, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K. Simon, and Wenyi Wei. Molecular subtypes and targeted therapeutic strategies in small cell lung cancer: advances, challenges, and future perspectives. Molecules, 30:1731, Apr 2025. URL: https://doi.org/10.3390/molecules30081731, doi:10.3390/molecules30081731. This article has 21 citations.

  5. (OpenTargets Search: small cell lung cancer): Open Targets Query (small cell lung cancer, 41 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  6. (megyesfalvi2023clinicalinsightsinto pages 5-5): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  7. (huang2023incidencesurvivalcomparison pages 1-2): Liling Huang, Yu Feng, Tongji Xie, Haohua Zhu, Le Tang, and Yuankai Shi. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer. BMC Cancer, Apr 2023. URL: https://doi.org/10.1186/s12885-023-10797-3, doi:10.1186/s12885-023-10797-3. This article has 24 citations and is from a peer-reviewed journal.

  8. (uprety2025trendsinthe pages 1-2): Dipesh Uprety, Randell Seaton, Abesh Niroula, Tarik Hadid, Kaushal Parikh, and Julie J. Ruterbusch. Trends in the incidence and survival outcomes in patients with small cell lung cancer in the united states: an analysis of the seer database. Cancer Medicine, Feb 2025. URL: https://doi.org/10.1002/cam4.70608, doi:10.1002/cam4.70608. This article has 17 citations and is from a peer-reviewed journal.

  9. (uprety2025trendsinthe pages 2-4): Dipesh Uprety, Randell Seaton, Abesh Niroula, Tarik Hadid, Kaushal Parikh, and Julie J. Ruterbusch. Trends in the incidence and survival outcomes in patients with small cell lung cancer in the united states: an analysis of the seer database. Cancer Medicine, Feb 2025. URL: https://doi.org/10.1002/cam4.70608, doi:10.1002/cam4.70608. This article has 17 citations and is from a peer-reviewed journal.

  10. (megyesfalvi2023clinicalinsightsinto pages 27-27): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  11. (redin2024smarca4controlsstate pages 1-2): Esther Redin, Harsha Sridhar, Yingqian A. Zhan, Barbara Pereira Mello, Hong Zhong, Vidushi Durani, Amin Sabet, Parvathy Manoj, Irina Linkov, Juan Qiu, Richard P. Koche, Elisa de Stanchina, Maider Astorkia, Doron Betel, Álvaro Quintanal-Villalonga, and Charles M. Rudin. Smarca4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and rest splicing. Journal of Hematology & Oncology, Jul 2024. URL: https://doi.org/10.1186/s13045-024-01572-3, doi:10.1186/s13045-024-01572-3. This article has 41 citations and is from a domain leading peer-reviewed journal.

  12. (huang2025molecularsubtypesand pages 7-9): Daoyuan Huang, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K. Simon, and Wenyi Wei. Molecular subtypes and targeted therapeutic strategies in small cell lung cancer: advances, challenges, and future perspectives. Molecules, 30:1731, Apr 2025. URL: https://doi.org/10.3390/molecules30081731, doi:10.3390/molecules30081731. This article has 21 citations.

  13. (huang2025molecularsubtypesand pages 2-4): Daoyuan Huang, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K. Simon, and Wenyi Wei. Molecular subtypes and targeted therapeutic strategies in small cell lung cancer: advances, challenges, and future perspectives. Molecules, 30:1731, Apr 2025. URL: https://doi.org/10.3390/molecules30081731, doi:10.3390/molecules30081731. This article has 21 citations.

  14. (patel2023smallcelllung pages 1-2): Shruti R. Patel and Millie Das. Small cell lung cancer: emerging targets and strategies for precision therapy. Cancers, 15:4016, Aug 2023. URL: https://doi.org/10.3390/cancers15164016, doi:10.3390/cancers15164016. This article has 39 citations.

  15. (redin2024smallcelllung pages 4-6): Esther Redin, Álvaro Quintanal-Villalonga, and Charles M. Rudin. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends in Cancer, 10:935-946, Oct 2024. URL: https://doi.org/10.1016/j.trecan.2024.07.008, doi:10.1016/j.trecan.2024.07.008. This article has 47 citations and is from a peer-reviewed journal.

  16. (redin2024smallcelllung pages 11-13): Esther Redin, Álvaro Quintanal-Villalonga, and Charles M. Rudin. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends in Cancer, 10:935-946, Oct 2024. URL: https://doi.org/10.1016/j.trecan.2024.07.008, doi:10.1016/j.trecan.2024.07.008. This article has 47 citations and is from a peer-reviewed journal.

  17. (redin2024smallcelllung pages 13-14): Esther Redin, Álvaro Quintanal-Villalonga, and Charles M. Rudin. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends in Cancer, 10:935-946, Oct 2024. URL: https://doi.org/10.1016/j.trecan.2024.07.008, doi:10.1016/j.trecan.2024.07.008. This article has 47 citations and is from a peer-reviewed journal.

  18. (huang2025molecularsubtypesand pages 13-15): Daoyuan Huang, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K. Simon, and Wenyi Wei. Molecular subtypes and targeted therapeutic strategies in small cell lung cancer: advances, challenges, and future perspectives. Molecules, 30:1731, Apr 2025. URL: https://doi.org/10.3390/molecules30081731, doi:10.3390/molecules30081731. This article has 21 citations.

  19. (megyesfalvi2023clinicalinsightsinto pages 6-7): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  20. (chen2024advancesinpredictive pages 2-4): Tong Chen, Mingzhao Wang, Yanchao Chen, Yang Cao, and Yutao Liu. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer. Cell & Bioscience, Sep 2024. URL: https://doi.org/10.1186/s13578-024-01283-9, doi:10.1186/s13578-024-01283-9. This article has 24 citations and is from a peer-reviewed journal.

  21. (papavassiliou2024p53andrb pages 4-5): Kostas A. Papavassiliou, Amalia A. Sofianidi, Vassiliki A. Gogou, Nektarios Anagnostopoulos, and Athanasios G. Papavassiliou. P53 and rb aberrations in small cell lung cancer (sclc): from molecular mechanisms to therapeutic modulation. International Journal of Molecular Sciences, 25:2479, Feb 2024. URL: https://doi.org/10.3390/ijms25052479, doi:10.3390/ijms25052479. This article has 39 citations.

  22. (zugazagoitia2024factsandhopes pages 2-3): Jon Zugazagoitia, Handerson Osma, Javier Baena, Alvaro C. Ucero, and Luis Paz-Ares. Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2872-2883, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-1159, doi:10.1158/1078-0432.ccr-23-1159. This article has 29 citations.

  23. (megyesfalvi2023clinicalinsightsinto pages 10-11): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  24. (chen2024aretrospectivestudy pages 1-2): Yao Chen, Ling Yao, Qingquan Chen, Yiming Hu, Xi Zhu, Rongrong Dai, Xiaoyang Chen, Yifu Zeng, Yong Zhu, Duanhong Song, and Yixiang Zhang. A retrospective study on the impact of radiotherapy on the survival outcomes of small cell lung cancer patients based on the seer database. Scientific Reports, Jul 2024. URL: https://doi.org/10.1038/s41598-024-65314-8, doi:10.1038/s41598-024-65314-8. This article has 8 citations and is from a peer-reviewed journal.

  25. (cheng2024benmelstobartanlotiniband pages 1-2): Ying Cheng, Jianhua Chen, Wei Zhang, Chao Xie, Qun Hu, Ningning Zhou, Chun Huang, Shihong Wei, Hong Sun, Xingya Li, Yan Yu, Jinhuo Lai, Huaping Yang, Haohui Fang, Hualin Chen, Peng Zhang, Kangsheng Gu, Qiming Wang, Jianhua Shi, Tienan Yi, Xingxiang Xu, Xianwei Ye, Daqing Wang, Conghua Xie, Chunling Liu, Yulong Zheng, Daren Lin, Wu Zhuang, Ping Lu, Guohua Yu, Jinzhang Li, Yuhai Gu, Baolan Li, Rong Wu, Ou Jiang, Zaiyi Wang, Guowu Wu, Haifeng Lin, Diansheng Zhong, Yanhua Xu, Yongqian Shu, Di Wu, Xingwu Chen, Jie Wang, Minghui Wang, and Runxiang Yang. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nature Medicine, 30:2967-2976, Jul 2024. URL: https://doi.org/10.1038/s41591-024-03132-1, doi:10.1038/s41591-024-03132-1. This article has 154 citations and is from a highest quality peer-reviewed journal.

  26. (megyesfalvi2023clinicalinsightsinto pages 9-9): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  27. (megyesfalvi2023clinicalinsightsinto pages 10-10): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  28. (bonanno2024realworldimpactof pages 1-2): Laura Bonanno, Lorenzo Calvetti, Alessandro Dal Maso, Alberto Pavan, Loc Carlo Bao, Mattia De Nuzzo, Stefano Frega, Giulia Sartori, Alessandra Ferro, Giulia Pasello, Paolo Morandi, Giuseppe Aprile, and Valentina Guarneri. Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2024.1353889, doi:10.3389/fimmu.2024.1353889. This article has 11 citations and is from a peer-reviewed journal.

  29. (zugazagoitia2024factsandhopes pages 3-3): Jon Zugazagoitia, Handerson Osma, Javier Baena, Alvaro C. Ucero, and Luis Paz-Ares. Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2872-2883, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-1159, doi:10.1158/1078-0432.ccr-23-1159. This article has 29 citations.

  30. (megyesfalvi2023clinicalinsightsinto pages 19-20): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  31. (zugazagoitia2024factsandhopes pages 7-8): Jon Zugazagoitia, Handerson Osma, Javier Baena, Alvaro C. Ucero, and Luis Paz-Ares. Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2872-2883, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-1159, doi:10.1158/1078-0432.ccr-23-1159. This article has 29 citations.

  32. (bonanno2024realworldimpactof pages 3-5): Laura Bonanno, Lorenzo Calvetti, Alessandro Dal Maso, Alberto Pavan, Loc Carlo Bao, Mattia De Nuzzo, Stefano Frega, Giulia Sartori, Alessandra Ferro, Giulia Pasello, Paolo Morandi, Giuseppe Aprile, and Valentina Guarneri. Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2024.1353889, doi:10.3389/fimmu.2024.1353889. This article has 11 citations and is from a peer-reviewed journal.

  33. (zugazagoitia2024factsandhopes pages 5-6): Jon Zugazagoitia, Handerson Osma, Javier Baena, Alvaro C. Ucero, and Luis Paz-Ares. Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2872-2883, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-1159, doi:10.1158/1078-0432.ccr-23-1159. This article has 29 citations.

  34. (patel2023smallcelllung pages 6-8): Shruti R. Patel and Millie Das. Small cell lung cancer: emerging targets and strategies for precision therapy. Cancers, 15:4016, Aug 2023. URL: https://doi.org/10.3390/cancers15164016, doi:10.3390/cancers15164016. This article has 39 citations.

  35. (sen2024emergingadvancesin pages 1-3): Triparna Sen, Nobuyuki Takahashi, Subhamoy Chakraborty, Naoko Takebe, Amin H. Nassar, Nagla A. Karim, Sonam Puri, and Abdul Rafeh Naqash. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nature reviews. Clinical oncology, 21:610-627, Jul 2024. URL: https://doi.org/10.1038/s41571-024-00914-x, doi:10.1038/s41571-024-00914-x. This article has 137 citations.

  36. (eglenenpolat2024atelomeretargetingdrug pages 1-2): Buse Eglenen-Polat, Ryan R. Kowash, Hai-Cheng Huang, Silvia Siteni, Mingrui Zhu, Kenian Chen, Matthew E. Bender, Ilgen Mender, Victor Stastny, Benjamin J. Drapkin, Prithvi Raj, John D. Minna, Lin Xu, Jerry W. Shay, and Esra A. Akbay. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-024-44861-8, doi:10.1038/s41467-024-44861-8. This article has 27 citations and is from a highest quality peer-reviewed journal.

Artifacts